Generate Biomedicines
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Generate Biomedicines sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Generate Biomedicines: 5 sponsored US clinical trials, 3 recruiting.
Generate Biomedicines sponsors 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 1 completed. 2 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Severe Asthma, with 2 trials.
Upper-quartile sponsor footprint
Generate Biomedicines sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
NCT07484022
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
NCT07359846
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
NCT07276724
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
NCT07116889
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants
NCT07050511
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Generate Biomedicines pipeline
3 recruiting of 5 indexed (60% open); 1 completed (20%).
Phase mix: 2 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Severe Asthma (2 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Generate Biomedicines: open-pipeline peers nationwide
Peers matched on 5 registered trials and 60% open enrollment, not the therapeutic-area sidebar.
Generate Biomedicines sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 60% open enrollment (± trial volume)
- Alaska Native Tribal Health Consortium · 60% recruiting · 5 trials
- Anwaar Saeed · 60% recruiting · 5 trials
- Autolus Limited · 60% recruiting · 5 trials
- Beam Therapeutics · 60% recruiting · 5 trials
Related
What to do with this Generate Biomedicines page
5 registered trials is a research-attention snapshot, not an endorsement of Generate Biomedicines or any single study.
- 3 of Generate Biomedicines's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Severe Asthma is the condition Generate Biomedicines studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Severe Asthma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Generate Biomedicines pipeline card: 5 registered trials from official public datasets.Report a data error.